Provide a clinical management algorithm (e.g.: flowchart) explaining the expected management and any downstream services (aftercare) of the eligible population/s if public funding is recommended for the service proposed. Clinical Management Algorithm for Coil System A proposed clinical management algorithm for the coil procedure is outlined on page 33. Emphysema presents specific treatment challenges, due mainly to collateral ventilation, disease distribution (upper and lower lobes) and disease diffusion (heterogeneous and homogenous) and patient frailty, resulting in patients presenting with co-morbidities who are prone to COPD exacerbations and respiratory events. They often require intensive specialist assessment and intervention. The Coil is designed to work independently of collateral ventilation, is effective in treating upper and lower lobes and effectively treats heterogeneous and homogeneous emphysema. Patients unsuitable for any endoscopic treatment are those with a homogenous disease distribution and very high (>75%) tissue destruction, as well as heterogeneous patients whose fissures are not intact and who have very high (>75%) tissue destruction. There are two non-implant treatment techniques which are not currently available due to removal from their commercial markets (Aeris® Aeriseal polymer foam sealant, and Uptake Medical thermal vapor ablation). Proposed Aftercare following treatment Patients are required to attend a follow up appointment following the procedure and return to the rendering physician's care in the event of adverse event, otherwise the patient can return to referring physicians for standard care and management. No further costs are expected with this therapy.
Provide a clinical management algorithm (e.g.: flowchart) explaining the expected management and any downstream services (aftercare) of the eligible population/s if public funding is recommended for the service proposed. Clinical Management Algorithm for Coil System A proposed clinical management algorithm for the coil procedure is outlined on page 33. Emphysema presents specific treatment challenges, due mainly to collateral ventilation, disease distribution (upper and lower lobes) and disease diffusion (heterogeneous and homogenous) and patient frailty, resulting in patients presenting with co-morbidities who are prone to COPD exacerbations and respiratory events. They often require intensive specialist assessment and intervention. The Coil is designed to work independently of collateral ventilation, is effective in treating upper and lower lobes and effectively treats heterogeneous and homogeneous emphysema. Patients unsuitable for any endoscopic treatment are those with a homogenous disease distribution and very high (>75%) tissue destruction, as well as heterogeneous patients whose fissures are not intact and who have very high (>75%) tissue destruction. There are two non-implant treatment techniques which are not currently available due to removal from their commercial markets (Aeris® Aeriseal polymer foam sealant, and Uptake Medical thermal vapor ablation). Proposed Aftercare following treatment Patients are required to attend a follow up appointment following the procedure and return to the rendering physician's care in the event of adverse event, otherwise the patient can return to referring physicians for standard care and management. No further costs are expected with this therapy.
1401-EndobronchialCoil-RatifiedFinalProtocol-accessible.docx